Cidara Therapeutics Inc (NASDAQ:CDTX)’s traded shares stood at 1.43 million during the last session, with the company’s beta value hitting 0.95. At the close of trading, the stock’s price was $0.84, to imply an increase of 13.80% or $0.1 in intraday trading. The CDTX share’s 52-week high remains $1.48, putting it -76.19% down since that peak but still an impressive 29.76% since price per share fell to its 52-week low of $0.59. The company has a valuation of $76.31M, with an average of 0.81 million shares in intraday trading volume over the past 10 days and average of 521.37K shares over the past 3 months.
Cidara Therapeutics Inc (NASDAQ:CDTX) trade information
After registering a 13.80% upside in the last session, Cidara Therapeutics Inc (CDTX) has traded red over the past five days. The stock hit a weekly high of 0.8500, jumping 13.80% in its intraday price action. The 5-day price performance for the stock is 10.35%, and 15.56% over 30 days. With these gigs, the year-to-date price performance is 6.06%. Short interest in Cidara Therapeutics Inc (NASDAQ:CDTX) saw shorts transact 0.22 million shares and set a 0.4 days time to cover.
Cidara Therapeutics Inc (CDTX) estimates and forecasts
Looking at statistics comparing Cidara Therapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. Cidara Therapeutics Inc (CDTX) shares are -14.07% down over the last 6 months, with its year-to-date growth rate higher than industry average at 34.88% against 12.60%. The rating firms project that company’s revenue will shrink -10.00% compared to the previous financial year.
Revenue forecast for the current quarter as set by 3 analysts is $11.54 million. Meanwhile, for the quarter ending Mar 2024, a total of 2 analyst(s) estimate revenue growth to $13.05 million.Earnings reports from the last fiscal year show that sales brought in $10.22 million and $25.99 million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 12.90% before dropping -49.80% in the following quarter.
CDTX Dividends
Cidara Therapeutics Inc has its next earnings report out between May 09 and May 13. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Cidara Therapeutics Inc has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Cidara Therapeutics Inc (NASDAQ:CDTX)’s Major holders
Cidara Therapeutics Inc insiders hold 7.53% of total outstanding shares, with institutional holders owning 30.91% of the shares at 33.42% float percentage. In total, 30.91% institutions holds shares in the company, led by BVF Inc.. As of Jun 29, 2023, the company held over 6.86 million shares (or 7.60% of shares), all amounting to roughly $7.75 million.
The next major institution holding the largest number of shares is Nantahala Capital Management, LLC with 3.96 million shares, or about 4.39% of shares outstanding. As of the market price on Jun 29, 2023, these shares were worth $4.48 million.
We also have Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Cidara Therapeutics Inc (CDTX) shares. Going by data provided on Jun 29, 2023, Vanguard Total Stock Market Index Fund holds roughly 2.17 million shares. This is just over 2.40% of the total shares, with a market valuation of $2.45 million. Data from the same date shows that the other fund manager holds a little less at 0.91 million, or 1.01% of the shares, all valued at about 1.03 million.
